Sgnlva-002: Single Arm, Open-Label, Phase Ib/Ii Study Of Ladiratuzumab Vedotin (Lv) In Combination With Pembrolizumab For First-Line Treatment Of Triple-Negative Breast Cancer
Annals of Oncology（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要